INCREASED PROLIFERATION OF A HUMAN BREAST-CARCINOMA CELL-LINE BY RECOMBINANT INTERLEUKIN-2

被引:18
|
作者
KATANO, M
MATSUO, T
MORISAKI, T
NAITO, K
NAGUMO, F
KUBOTA, E
NAKAMURA, M
HISATSUGU, T
TADANO, J
机构
[1] KYUSHU UNIV,SCH MED,DEPT SURG 1,FUKUOKA 812,JAPAN
[2] SAGA MED SCH,DEPT INTERNAL MED,SAGA 849,JAPAN
[3] SAGA MED SCH,HOSP LAB,SAGA 849,JAPAN
[4] SAGA MED SCH,DEPT ORAL & MAXILLOFACIAL SURG,SAGA 849,JAPAN
关键词
BREAST CARCINOMA CELL LINE; INTERLEUKIN-2; RECEPTOR; AUTOCRINE GROWTH FACTOR; SECRETION;
D O I
10.1007/BF01533381
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Two adenocarcinoma cell lines, Breast M25-SF and Breast M, were established from tumor tissue resected surgically from a patient with breast cancer. One, Breast M25-SF, expresses interleukin-2 receptor (IL-2R) on the cell surface and the other, Breast M, does not. The effects of recombinant interleukin-2 (rIL-2) on the proliferation of these cell lines were investigated. The growth of Breast M25-SF was significantly promoted by rIL-2 ranging from 1.25 U/ml to 640 U/ml. Anti-CD25 (Tac) antibody significantly blocked the growth enhancement of Breast M25-SF by rIL-2. Breast M, however, did not respond to rIL-2. To confirm more directly the promotion of Breast M25-SF growth by rIL-2, cloning of IL-2 responders from parent Breast M25-SF cells was carried out by limiting dilution without feeder cells in 96-well microplates. No colony formation was found in 24 wells without rIL-2. Eleven, 13 and 6 clones were established from groups of 24 wells containing rIL-2 at 200, 20 and 2 U/ml respectively. All of the clones expressed IL-2R and respond to rIL-2. By using a sensitive polymerase chain reaction technique, we demonstrated that Breast M25-SF but not Breast M expressed IL-2 mRNA, and IL-2 secretion from Breast M25-SF but not Breast M was also confirmed by radioimmunoassay. These findings suggest a role for IL-2 in autocrine support of Breast M25-SF growth. IL-2 may play an important role in the growth control of breast carcinoma cells.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 50 条
  • [31] The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis
    Shen, Hong
    Min, Rui
    Tan, Qi
    Xie, Weiping
    Wang, Hong
    Pan, Hongqiu
    Zhang, Li
    Xu, Hongtao
    Zhang, Xia
    Dai, Jianzhong
    ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (03) : 584 - 590
  • [32] Release of recombinant human interleukin-2 from dextran-based hydrogels
    Cadée, JA
    de Groot, CJ
    Jiskoot, W
    den Otter, W
    Hennink, WE
    JOURNAL OF CONTROLLED RELEASE, 2002, 78 (1-3) : 1 - 13
  • [33] Combination treatment with interleukin-2 and interleukin-12 for murine renal cell carcinoma
    Onishi T.
    Ohishi Y.
    Goto H.
    Imagawa K.-I.
    Ohmoto Y.
    Wada K.
    International Journal of Clinical Oncology, 1999, 4 (6) : 364 - 371
  • [34] INVITRO AND INVIVO EFFECTS OF RECOMBINANT HUMAN INTERLEUKIN-2 IN NAIVE MINIATURE SWINE
    NAKAJIMA, K
    SMITH, CV
    MIXON, A
    SYKES, M
    GUZZETTA, PC
    SPITZER, TR
    ECKHAUS, MA
    SACHS, DH
    JOURNAL OF IMMUNOTHERAPY, 1992, 11 (03): : 169 - 175
  • [35] Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma
    Chi, KH
    Myers, JN
    Chow, KC
    Chan, WK
    Tsang, YW
    Chao, Y
    Yen, SH
    ONCOLOGY, 2001, 60 (02) : 110 - 115
  • [36] Combined levamisole with recombinant interleukin-2 (IL-2) in patients with advanced renal cell carcinoma - A phase II study
    Creagan, ET
    Hestorrf, RD
    Suman, VJ
    Mailliard, JA
    Nair, S
    Krook, JE
    Kugler, JW
    Marschke, RF
    Michalak, JC
    Tschetter, LK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (02): : 139 - 141
  • [37] Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    Fisher, RI
    Rosenberg, SA
    Fyfe, G
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 2000, 6 : S55 - S57
  • [38] The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma
    Antonio Romo de Vivar Chavez
    Michael E. de Vera
    Xiaoyan Liang
    Michael T. Lotze
    Medical Oncology, 2009, 26 : 3 - 12
  • [39] Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2
    Merimsky, O
    Gez, E
    Weitzen, R
    Nehushtan, H
    Rubinov, R
    Hayat, H
    Peretz, T
    Ben-Shahar, M
    Biran, H
    Katsenelson, R
    Mermershtein, V
    Loven, D
    Karminsky, N
    Neumann, A
    Matcejevsky, D
    Inbar, M
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 610 - 612
  • [40] The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma
    de Vivar Chavez, Antonio Romo
    de Vera, Michael E.
    Liang, Xiaoyan
    Lotze, Michael T.
    MEDICAL ONCOLOGY, 2009, 26 : 3 - 12